This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $371,627 to the University of Texas Medical Branch at Galveston (UTMB) to support research on "TARGETING RETINOID ACID METABOLIC PATHWAY TO TREAT NOISE-INDUCED HEARING LOSS". The research aims to investigate the use of selective CYP26 inhibitors as a treatment for noise-induced hearing loss, with potential to transform care for Service Members and the public. UTMB has subcontracted a portion of the work to Dermaxon LLC, a biotech company specializing in skin disease and pain research, to develop novel CYP26 inhibitors that may provide an effective treatment approach with fewer side effects than existing options. This multi-year research project runs from Sep 1, 2023 to Aug 31, 2025.
Generated 6/11/24, 1:53 PM